Navigation Links
Forterus Treatment Center, A Better Tomorrow, Featured in Major Network Program
Date:5/22/2009

HUNTINGTON BEACH, Calif., May 22 /PRNewswire-FirstCall/ -- Forterus Inc. (Pink Sheets: FTER), owner and operator of the "A Better Tomorrow" Treatment Center, Inc. in Murrieta, California, said today that the documentary "Intervention," which features this Forterus facility, will be aired on the A & E Network at 7 p.m. Eastern and Pacific on Monday, May 25th.

"Intervention" is a reality based TV series featuring people who are seeking a route to redemption from such dependencies as drugs and alcohol. "A Better Tomorrow is dedicated to serving the middle class, not just Hollywood elites, and is notable because it has a separate treatment program for adolescents, and Spanish-language treatment services," said Paul Howarth, founder and CEO.

For more information about Forterus, and the variety of healthcare services it provides, including behavioral, intervention services, drug and alcohol rehabilitation, pain management and physical therapy, visit www.forterushealthcare.com and www.abttc.com.

    CONTACT:

        Paul Howarth, CEO
        888/257-8345
        ir@forterushealthcare.com

        Paul Knopick
        E & E Communications
        949/707-5365
        pknopick@eandecommunications.com


'/>"/>
SOURCE Forterus Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. A Better Tomorrow Treatment Center Inc., a Forterus Subsidiary, to Be Featured On A & E Television Networks Intervention Program
2. Forterus Healthcare Continues Its Southern California Expansion, Completing Its Second Acquisition in Six Months
3. Forterus Healthcare to Acquire Solutions 4 Recovery
4. Forterus Inc. Announces Stock Buyback
5. Forterus Inc. Inks Agreement to Provide National Sales and Marketing Support for a North Carolina-Based Addiction Treatment Center
6. African-American women with advanced breast cancer often forego vital treatment
7. AIDS Treatment Activists Push UNAIDS and WHO to Meet Commitments to Reduce HIV in Women and Newborns
8. Fertility Treatment Twins More at Risk for Hospitalizations
9. Clinical Topicals Makes Breakthrough Migraine Treatment Available Free to Soldiers
10. Protein that suppresses androgen receptors could improve prostate cancer diagnosis, treatment
11. With Heart Attacks, Fast Treatment Matters

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...tes Department of Agriculture (USDA) has awarded a... University of Minnesota to complete sequencing th...lopavo. The funding will be used by the Turkey Gen...equencing using next-generation sequencing platfor...es and functions in the final genome sequence by u...
(Date:11/23/2009)...-FirstCall/--AnnTaylorStoresCorp.announcedtodaytha...lThanksandGivingcampaign,aholidayfundraisingandawa...ThisyearmarksthethirdyearthatAnnTaylor,throughitsA...nthecampaignwhereweofferourshoppersanopportunityto...ppingthisholidayseason.ClientswhoshopatAnnTaylor,L...
(Date:11/23/2009)...ire/--Thanksgivingweekendmarksthe36thannualStateFa...icrepresentsthesportsmanshipandprideoftwoschoolsbu...hoseinattendance. ,, ForthecrewofthenewU.S.Coas...mebeforetheyworktotestandlaunchabrandnewshiptoprot...ttyOfficerClaudeBovellandtherestofthecrewwillbegin...
(Date:11/23/2009)...ally modified to produce bacterial proteins that a...have been planted on more than 200 million hectare...ed after the bacterium Bacillus thuringiensis , c...allowing farmers to save money and lessen environm...However, since insects can evolve resistance to to...
(Date:11/23/2009)...ger to get sick, study finds , , MONDAY,...t a genetic variation appears to play a major role...tients. , In fact, those with the variation a... of complications of the disease. , "We,re ho...at make a person more or less susceptible to HIV, ...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2Health News:Nothing Is Like Being There 2Health News:Insect resistance to Bt crops can be predicted, monitored and managed 2Health News:Genetic Variant Slows AIDS Progression 2
... Leading Researchers to Discuss, State of Breast ... Cures, BOSTON, April 9 The Massachusetts Affili...posium April 10 at Harvard Medical,School, featuri...d the need for more funding to ensure that critica...
...s becoming popular, survey finds , , WEDNE...ondents to a new survey acknowledges using so-call... heart medications -- to stimulate their focus, co...ut has emerged in recent years as a campus "study ...
...Care and Frida,Kahlo Store are proud to announce t...8 for the benefit of The Leukemia & Lymphoma Socie...sance, located at 2131 Hylan,Boulevard, Staten Isl... problems., The event will consist of a dinner-co...
...ia,Academy of Family Physicians Foundation (PAFP/F...amily medicine student scholarship programs., "Th...dle the continuing,demand for primary care," said ...we have to make sure they get every,opportunity to...
...n the United,States has doubled in the last 30 yea...tom lines, according to a new report from The Conf... fit the definition of "obese.",Obese employees co...yers Should Know about,Obesity, The Conference Boa...
...ingerprint associated with normal embryonic stem c...tion of cancer stem cells. The research, published...m Cell, demonstrates that embryonic stem cells and...nificant clinical implications for cancer therapeu...
Other Medicine News:Health News:Massachusetts Affiliate of Susan G. Komen for the Cure to Spotlight Gaps in Breast Cancer Research 2Health News:Unlikely Drugs Emerge as 'Cognition Enhancers' 2Health News:PAFP Golf Tournament to Benefit Student Programs 2Health News:Obesity Costs U.S. Companies as Much as $45 Billion a Year, The Conference Board Reports 2Health News:Obesity Costs U.S. Companies as Much as $45 Billion a Year, The Conference Board Reports 3Health News:Module map links embryonic stem cells and cancer stem cells 2
(Date:11/23/2009)...,Texas,Nov.23/PRNewswire-FirstCall/-- LexiconPharm...top-linedatafromitsPhase2clinicalstudywith LX1031 ...me(IBS)willbepresentedatGASTRO2009inLondonthisweek...ementinIBSsymptoms,willbepresentedbyDr. PhilipM.Br...ment,onNovember25,2009at2:30pmlocaltimeatthesessio...
(Date:11/23/2009)...xas,Nov.23/PRNewswire-FirstCall/--WoundManagementT...owingproviderofspecialtymedicalproducts,announcedt...dacomprehensivemanagementbusinessupdatetoillustrat...Q32009salesincreased33.5%to$102,926vs.Q32008saleso...reasedto$3,327,892vs.Q32008shareholderequityof$(32...
(Date:11/23/2009)...CISCO,Calif.,Nov.23/PRNewswire-FirstCall/--Anesiva...andDr.DavidC.U,PrichardhaveagreedtojointheAnesivab...gerbetweenAnesivaandArcionTherapeutics.Completiono...keplaceatthepreviouslyannouncedAnesiva2009AnnualMe...a.m.PSTat400OysterPoint,Suite107A,SouthSanFrancisc...
Breaking Medicine Technology:Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 1FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 2FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 3FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 4FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 5FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 6For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 1For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 2For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 1NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 2NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 4NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 5NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 6NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 7NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 8
...rch 19 Phosphagenics,Limited (ASX: POH, AIM: PSG,...d ethics approval to commence treating patients wi...ng its patented transdermal insulin delivery,syste... the trial will be,Dr. Michael D, Emden, Departmen...pital, and William Hsu, who is an Assistant Invest...
...at SIR Meeting Indicates New Catheter-based, Trea...reating Acute DVT, WASHINGTON, March 19 Registry...of Interventional Radiology,s 33rd Annual,Scientif... Peripheral,Infusion System from Bacchus Vascular,... blood clot in most patients in about 20 minutes.,...
Other Medicine Technology:Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 2Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 3Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients 2
...6 mm tip is angled 90 degrees with 1 mm flattened ...ure extension tube (0.03 inch ID x 8 inch long), f...r dissecting pre-retinal and other vitreo-retinal ..., angled tip of 30 gauge cannula facilitates place...
Vitreoretinal Micro Cannula
Moist Air Humidifying Chambers
Eye Garter Shield Cover - white
Medicine Products: